Highest-materiality recent filing
Jupiter Neurosciences signs exclusive US license for PharmAla's ALA-002 MDMA program
Upfront payment of $3.33M: $1.5M cash (net of $600K escrow) plus $1.83M in Jupiter common stock.
Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA
Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.
Jupiter Neurosciences receives Nasdaq deficiency notices for bid price and market value
Two Nasdaq deficiency notices received Feb 26, 2026: bid price <$1.00 for 30 consecutive days.
Authorized common stock increased from 125M to 500M shares via amendment approved by 20.2M votes for, 4.5M against.
Jupiter Neurosciences secures up to $20M flexible financing from Yorkville; $4M funded at signing
Initial $4M pre-paid advance funded via convertible note with $1.50 fixed conversion price and 7% OID.
Jupiter Neurosciences receives Nasdaq delisting notice for bid price non-compliance
Nasdaq notified JUNS on Mar 21, 2025 that bid price closed below $1.00 for 30 consecutive business days through Mar 20, 2025.
One-time payment of $2,300,000 to Dominant Treasure for services to accelerate product development and distribution in Southeast Asia.
Jupiter Neurosciences closes IPO on Nasdaq, raises $11M gross from 2.75M shares at $4.00
IPO of 2,750,000 common shares priced at $4.00/sh for gross proceeds of $11M.
On June 17, 2026, Allison W. Brady, a member of the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the “Company”), informed the Company of her decision to resign from the Board, effective immediately.
The Amendment appoints Ms. Silva as the Company’s Chief Operating Officer and President
Max materiality 0.80 · Median 0.53 · Most common event other_material